NCT05110209

Real-world Evaluation of Prevalence of Ocular Adverse Events in Patients With Neovascular (Wet) Agerelated Macular Degeneration (AMD) Who Received Anti-VEGF Agents (IRIS Registry)

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 331,541 (actual)
• Sponsor: Novartis Pharmaceuticals · Industry
• Sex: All
• Age: 18 Years – 85 Years
• Healthy volunteers: Not accepted

Summary

In this cross-sectional study of patients with wet AMD who received ≥1 anti-VEGF injection (excluding brolucizumab), evidence was generated to describe the period prevalence of specific ocular AEs. The study was conducted using the IRIS Registry, and all results were based on the study period from 01/01/2019 to 12/31/2019.

Detailed description

This was a retrospective cohort study of eyes in adult patients with a diagnosis of wet AMD who were treated with anti-VEGF agents from 01/01/2019 to 12/31/2019. IRIS Registry data from 01/01/2019 to 12/31/2019 for patients with a diagnosis of wet AMD who were treated with ≥1 anti-VEGF agent (excluding brolucizumab) were included. * Identification period: Patients fulfilling the selection criteria during the period from 01/01/2019 to 12/31/2019 were identified * Index date: 01/01/2019 * Study Period: 01/01/2019 to 12/31/2019 * Pre-index period: 01/01/2018 to 12/31/2018 * Post-index period: 01/01/2019 to 12/31/2019

Conditions

• Age-related Macular Degeneration (AMD)

Interventions

Type	Name	Description
OTHER	Aflibercept	intravitreal injection
OTHER	Ranibizumab	intravitreal injection
OTHER	Bevacizumab	intravitreal injection

Timeline

• Start date: 2020-07-15
• Primary completion: 2020-11-20
• Completion: 2020-11-20
• First posted: 2021-11-05
• Last updated: 2021-12-21

Locations

1 site across 1 country: United States